Emerging infectious agents
Identifieur interne : 000625 ( PascalFrancis/Corpus ); précédent : 000624; suivant : 000626Emerging infectious agents
Auteurs : D. A. LeibySource :
- Developments in biologicals [ 1424-6074 ] ; 2005.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
As new agents of infectious disease continue to emerge and old antagonists re-emerge, it is clear that the war on infectious disease is far from over. Indeed, the appearance of SARS during the past year is the latest example of the continuing challenges posed by agents of infectious disease. Emerging agents are threats not only to the general population, but also to recipients of blood transfusions. Today a variety of emerging agents are of concern to transfusion safety including Trypanosoma cruzi, West Nile virus, and Babesia microti to name but a few. These and other emerging agents have arisen or have been introduced partly through changes in donor demographics, international travel, microbial adaptations, land use, and human behaviour. Unfortunately, for many of these agents there is an absence of viable tests or other sound interventions to prevent their transmission at this time.
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
pA |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
pR |
|
Format Inist (serveur)
NO : | PASCAL 05-0368719 INIST |
---|---|
ET : | Emerging infectious agents |
AU : | LEIBY (D. A.); VYAS (G. N.); WILLIAMS (A. E.) |
AF : | Transmissible Diseases Department, Jerome H. Holland Laboratory for the Biomedical Sciences, American Red Cross/Rockville, MD/Etats-Unis (1 aut.); University of San Francisco/San Francisco, CA/Etats-Unis (1 aut.); Food and Drug Administration/Rockville, MD/Etats-Unis (2 aut.) |
DT : | Publication en série; Congrès; Niveau analytique |
SO : | Developments in biologicals; ISSN 1424-6074; Suisse; Da. 2005; Vol. 120; Pp. 11-15; Bibl. 15 ref. |
LA : | Anglais |
EA : | As new agents of infectious disease continue to emerge and old antagonists re-emerge, it is clear that the war on infectious disease is far from over. Indeed, the appearance of SARS during the past year is the latest example of the continuing challenges posed by agents of infectious disease. Emerging agents are threats not only to the general population, but also to recipients of blood transfusions. Today a variety of emerging agents are of concern to transfusion safety including Trypanosoma cruzi, West Nile virus, and Babesia microti to name but a few. These and other emerging agents have arisen or have been introduced partly through changes in donor demographics, international travel, microbial adaptations, land use, and human behaviour. Unfortunately, for many of these agents there is an absence of viable tests or other sound interventions to prevent their transmission at this time. |
CC : | 002A01D; 002A05C09 |
FD : | Trypanosoma cruzi; Virus West Nile; Babesia microti; Homme; Syndrome respiratoire aigu sévère; Receveur; Sang; Transfusion; Sécurité transfusionnelle; Adaptation; Transmission; Toxicité; Maladie émergente |
FG : | Kinetoplastida; Protozoa; Virus groupe encéphalite japonaise; Flavivirus; Flaviviridae; Virus; Apicomplexa; Virose; Infection |
ED : | Trypanosoma cruzi; West Nile virus; Babesia microti; Human; Severe acute respiratory syndrome; Recipient; Blood; Transfusion; Transfusion safety; Adaptation; Transmission; Toxicity; Emerging disease |
EG : | Kinetoplastida; Protozoa; Japanese encephalitis group virus; Flavivirus; Flaviviridae; Virus; Apicomplexa; Viral disease; Infection |
SD : | Trypanosoma cruzi; West Nile virus; Babesia microti; Hombre; Síndrome respiratorio agudo severo; Receptor; Sangre; Transfusión; Seguridad de la transfusión; Adaptación; Transmisión; Toxicidad; Enfermedad emergente |
LO : | INIST-13557.354000131443740020 |
ID : | 05-0368719 |
Links to Exploration step
Pascal:05-0368719Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Emerging infectious agents</title>
<author><name sortKey="Leiby, D A" sort="Leiby, D A" uniqKey="Leiby D" first="D. A." last="Leiby">D. A. Leiby</name>
<affiliation><inist:fA14 i1="01"><s1>Transmissible Diseases Department, Jerome H. Holland Laboratory for the Biomedical Sciences, American Red Cross</s1>
<s2>Rockville, MD</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">05-0368719</idno>
<date when="2005">2005</date>
<idno type="stanalyst">PASCAL 05-0368719 INIST</idno>
<idno type="RBID">Pascal:05-0368719</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000625</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Emerging infectious agents</title>
<author><name sortKey="Leiby, D A" sort="Leiby, D A" uniqKey="Leiby D" first="D. A." last="Leiby">D. A. Leiby</name>
<affiliation><inist:fA14 i1="01"><s1>Transmissible Diseases Department, Jerome H. Holland Laboratory for the Biomedical Sciences, American Red Cross</s1>
<s2>Rockville, MD</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Developments in biologicals</title>
<title level="j" type="abbreviated">Dev. biol.</title>
<idno type="ISSN">1424-6074</idno>
<imprint><date when="2005">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Developments in biologicals</title>
<title level="j" type="abbreviated">Dev. biol.</title>
<idno type="ISSN">1424-6074</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adaptation</term>
<term>Babesia microti</term>
<term>Blood</term>
<term>Emerging disease</term>
<term>Human</term>
<term>Recipient</term>
<term>Severe acute respiratory syndrome</term>
<term>Toxicity</term>
<term>Transfusion</term>
<term>Transfusion safety</term>
<term>Transmission</term>
<term>Trypanosoma cruzi</term>
<term>West Nile virus</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Trypanosoma cruzi</term>
<term>Virus West Nile</term>
<term>Babesia microti</term>
<term>Homme</term>
<term>Syndrome respiratoire aigu sévère</term>
<term>Receveur</term>
<term>Sang</term>
<term>Transfusion</term>
<term>Sécurité transfusionnelle</term>
<term>Adaptation</term>
<term>Transmission</term>
<term>Toxicité</term>
<term>Maladie émergente</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">As new agents of infectious disease continue to emerge and old antagonists re-emerge, it is clear that the war on infectious disease is far from over. Indeed, the appearance of SARS during the past year is the latest example of the continuing challenges posed by agents of infectious disease. Emerging agents are threats not only to the general population, but also to recipients of blood transfusions. Today a variety of emerging agents are of concern to transfusion safety including Trypanosoma cruzi, West Nile virus, and Babesia microti to name but a few. These and other emerging agents have arisen or have been introduced partly through changes in donor demographics, international travel, microbial adaptations, land use, and human behaviour. Unfortunately, for many of these agents there is an absence of viable tests or other sound interventions to prevent their transmission at this time.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>1424-6074</s0>
</fA01>
<fA03 i2="1"><s0>Dev. biol.</s0>
</fA03>
<fA05><s2>120</s2>
</fA05>
<fA08 i1="01" i2="1" l="ENG"><s1>Emerging infectious agents</s1>
</fA08>
<fA09 i1="01" i2="1" l="ENG"><s1>ATS 2003 Symposium: Advances in transfusion safety, Bethesda, MD, USA, June 4-6, 2003</s1>
</fA09>
<fA11 i1="01" i2="1"><s1>LEIBY (D. A.)</s1>
</fA11>
<fA12 i1="01" i2="1"><s1>VYAS (G. N.)</s1>
<s9>ed.</s9>
</fA12>
<fA12 i1="02" i2="1"><s1>WILLIAMS (A. E.)</s1>
<s9>ed.</s9>
</fA12>
<fA14 i1="01"><s1>Transmissible Diseases Department, Jerome H. Holland Laboratory for the Biomedical Sciences, American Red Cross</s1>
<s2>Rockville, MD</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA15 i1="01"><s1>University of San Francisco</s1>
<s2>San Francisco, CA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</fA15>
<fA15 i1="02"><s1>Food and Drug Administration</s1>
<s2>Rockville, MD</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</fA15>
<fA18 i1="01" i2="1"><s1>U.S. Food and Drug Administration</s1>
<s2>Rockville, MD</s2>
<s3>USA</s3>
<s9>org-cong.</s9>
</fA18>
<fA18 i1="02" i2="1"><s1>AABB American Association of Blood Banks</s1>
<s3>USA</s3>
<s9>org-cong.</s9>
</fA18>
<fA18 i1="03" i2="1"><s1>National Institute of Health NIH. National Heart, Lung, and Blood Institute</s1>
<s2>Bethesda, MD</s2>
<s3>USA</s3>
<s9>org-cong.</s9>
</fA18>
<fA18 i1="04" i2="1"><s1>U.S. Department of Defense</s1>
<s3>USA</s3>
<s9>org-cong.</s9>
</fA18>
<fA18 i1="05" i2="1"><s1>International Association for Biologicals (IABs)</s1>
<s2>Acacias-Geneva</s2>
<s3>CHE</s3>
<s9>org-cong.</s9>
</fA18>
<fA20><s1>11-15</s1>
</fA20>
<fA21><s1>2005</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>13557</s2>
<s5>354000131443740020</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2005 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>15 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>05-0368719</s0>
</fA47>
<fA60><s1>P</s1>
<s2>C</s2>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Developments in biologicals</s0>
</fA64>
<fA66 i1="01"><s0>CHE</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>As new agents of infectious disease continue to emerge and old antagonists re-emerge, it is clear that the war on infectious disease is far from over. Indeed, the appearance of SARS during the past year is the latest example of the continuing challenges posed by agents of infectious disease. Emerging agents are threats not only to the general population, but also to recipients of blood transfusions. Today a variety of emerging agents are of concern to transfusion safety including Trypanosoma cruzi, West Nile virus, and Babesia microti to name but a few. These and other emerging agents have arisen or have been introduced partly through changes in donor demographics, international travel, microbial adaptations, land use, and human behaviour. Unfortunately, for many of these agents there is an absence of viable tests or other sound interventions to prevent their transmission at this time.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002A01D</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002A05C09</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Trypanosoma cruzi</s0>
<s2>NS</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Trypanosoma cruzi</s0>
<s2>NS</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Trypanosoma cruzi</s0>
<s2>NS</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Virus West Nile</s0>
<s2>NW</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>West Nile virus</s0>
<s2>NW</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>West Nile virus</s0>
<s2>NW</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Babesia microti</s0>
<s2>NS</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Babesia microti</s0>
<s2>NS</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Babesia microti</s0>
<s2>NS</s2>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Homme</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Human</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Hombre</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Syndrome respiratoire aigu sévère</s0>
<s2>NM</s2>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Severe acute respiratory syndrome</s0>
<s2>NM</s2>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Síndrome respiratorio agudo severo</s0>
<s2>NM</s2>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Receveur</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Recipient</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Receptor</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Sang</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Blood</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Sangre</s0>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Transfusion</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Transfusion</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Transfusión</s0>
<s5>08</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Sécurité transfusionnelle</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Transfusion safety</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Seguridad de la transfusión</s0>
<s5>09</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Adaptation</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Adaptation</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Adaptación</s0>
<s5>10</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Transmission</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Transmission</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Transmisión</s0>
<s5>11</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Toxicité</s0>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Toxicity</s0>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Toxicidad</s0>
<s5>12</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Maladie émergente</s0>
<s2>NM</s2>
<s5>14</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Emerging disease</s0>
<s2>NM</s2>
<s5>14</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Enfermedad emergente</s0>
<s2>NM</s2>
<s5>14</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Kinetoplastida</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Kinetoplastida</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Kinetoplastida</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Protozoa</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Protozoa</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Protozoa</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Virus groupe encéphalite japonaise</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Japanese encephalitis group virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Japanese encephalitis group virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Flavivirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Flavivirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Flavivirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Flaviviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Flaviviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Flaviviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Apicomplexa</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Apicomplexa</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Apicomplexa</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Virose</s0>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Viral disease</s0>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Virosis</s0>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Infection</s0>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Infection</s0>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Infección</s0>
</fC07>
<fN21><s1>255</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
<pR><fA30 i1="01" i2="1" l="ENG"><s1>Advances in transfusion safety. Symposium</s1>
<s3>Bethesda, MD USA</s3>
<s4>2003-06-04</s4>
</fA30>
</pR>
</standard>
<server><NO>PASCAL 05-0368719 INIST</NO>
<ET>Emerging infectious agents</ET>
<AU>LEIBY (D. A.); VYAS (G. N.); WILLIAMS (A. E.)</AU>
<AF>Transmissible Diseases Department, Jerome H. Holland Laboratory for the Biomedical Sciences, American Red Cross/Rockville, MD/Etats-Unis (1 aut.); University of San Francisco/San Francisco, CA/Etats-Unis (1 aut.); Food and Drug Administration/Rockville, MD/Etats-Unis (2 aut.)</AF>
<DT>Publication en série; Congrès; Niveau analytique</DT>
<SO>Developments in biologicals; ISSN 1424-6074; Suisse; Da. 2005; Vol. 120; Pp. 11-15; Bibl. 15 ref.</SO>
<LA>Anglais</LA>
<EA>As new agents of infectious disease continue to emerge and old antagonists re-emerge, it is clear that the war on infectious disease is far from over. Indeed, the appearance of SARS during the past year is the latest example of the continuing challenges posed by agents of infectious disease. Emerging agents are threats not only to the general population, but also to recipients of blood transfusions. Today a variety of emerging agents are of concern to transfusion safety including Trypanosoma cruzi, West Nile virus, and Babesia microti to name but a few. These and other emerging agents have arisen or have been introduced partly through changes in donor demographics, international travel, microbial adaptations, land use, and human behaviour. Unfortunately, for many of these agents there is an absence of viable tests or other sound interventions to prevent their transmission at this time.</EA>
<CC>002A01D; 002A05C09</CC>
<FD>Trypanosoma cruzi; Virus West Nile; Babesia microti; Homme; Syndrome respiratoire aigu sévère; Receveur; Sang; Transfusion; Sécurité transfusionnelle; Adaptation; Transmission; Toxicité; Maladie émergente</FD>
<FG>Kinetoplastida; Protozoa; Virus groupe encéphalite japonaise; Flavivirus; Flaviviridae; Virus; Apicomplexa; Virose; Infection</FG>
<ED>Trypanosoma cruzi; West Nile virus; Babesia microti; Human; Severe acute respiratory syndrome; Recipient; Blood; Transfusion; Transfusion safety; Adaptation; Transmission; Toxicity; Emerging disease</ED>
<EG>Kinetoplastida; Protozoa; Japanese encephalitis group virus; Flavivirus; Flaviviridae; Virus; Apicomplexa; Viral disease; Infection</EG>
<SD>Trypanosoma cruzi; West Nile virus; Babesia microti; Hombre; Síndrome respiratorio agudo severo; Receptor; Sangre; Transfusión; Seguridad de la transfusión; Adaptación; Transmisión; Toxicidad; Enfermedad emergente</SD>
<LO>INIST-13557.354000131443740020</LO>
<ID>05-0368719</ID>
</server>
</inist>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000625 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000625 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= PascalFrancis |étape= Corpus |type= RBID |clé= Pascal:05-0368719 |texte= Emerging infectious agents }}
This area was generated with Dilib version V0.6.33. |